@article{10902/24489,
year = {2021},
month = {12},
url = {http://hdl.handle.net/10902/24489},
abstract = {Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE. This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ 50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ? 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.},
publisher = {Lippincott Williams & Wilkins},
publisher = {Medicine: December 23, 2021 - Volume 100 - Issue 51 - p e27597},
title = {Linezolid for infective endocarditis. A structured approach based on a national database experience},
author = {Muñoz, P. and De la Villa. S. and Martínez-Sellés, M. and Goenaga, M. A. and Reviejo-Jaka, K. and Arnáiz de las Revillas Almajano, Francisco and García-Cuello, L. and Hidalgo-Tenorio, Carmen and Rodríguez-Esteban, M. A. and Antorrena, I. and Castelo-Corral, L. and García-Vázquez, E. and De la Torre, J. and Bouza, E. and Fariñas Álvarez, María del Carmen},
}